Related Experiment Video
Updated: Jul 6, 2025
In Vitro Establishment of a Genetically Engineered Murine Head and Neck Cancer Cell Line using an Adeno-Associated Virus-Cas9 System
Published on: January 9, 2020
Development of Cas13a-based therapy for cancer treatment
Ying Dong1, Bingyang Zhang1, Yi Wei1
1Key Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, School of Laboratory Medicine and Biotechnology, Southern Medical University, 1023 Shatai Rd, Guangzhou, 510515, China.
Abstract:
Gene therapy has become a major focus of current biomedical research. CRISPR (Clustered Regularly Inter spaced Short Palindromic Repeats) systems have been extensively researched for disease treatment applications through genome editing specificity. Compared with Cas9 (CRISPR-associated proteins, Cas), a commonly used tool enzyme for genome editing, Cas13a exhibits RNA-dependent endonuclease activity, including collateral cleavage without obvious potential genetic risks. With its high specificity, Cas13a has significantly improved the sensitivity of viral diagnosis and shown potential to eliminate viruses. However, its efficacy in tumor therapy has not been determined. This review introduces the mechanism and research developments associated with the CRISPR-Cas13a system in tumor treatments and its potential to be used as a new tool for gene therapy. We hope more research would apply Cas13a-based therapy in cancer treatment in the future.
Insights
CRISPR-Cas13a, a novel gene editing tool, offers RNA targeting with high specificity and low genetic risk. This review explores its potential for innovative cancer treatment and gene therapy applications.
Area of Science:
- Biomedical Research
- Molecular Biology
- Gene Therapy
Background:
- CRISPR systems are key for genome editing in disease treatment.
- Cas13a, unlike Cas9, targets RNA and has collateral cleavage activity.
- Cas13a shows promise in viral diagnosis and elimination but its tumor therapy efficacy is unknown.
Purpose of the Study:
- To review the mechanism and research progress of CRISPR-Cas13a in tumor treatments.
- To evaluate the potential of Cas13a as a novel gene therapy tool for cancer.
Main Methods:
- Review of existing literature on CRISPR-Cas13a systems.
- Analysis of Cas13a's RNA-dependent endonuclease activity and specificity.
- Exploration of Cas13a's application in viral diagnosis and potential for tumor therapy.
Main Results:
- Cas13a demonstrates high specificity and RNA-targeting capabilities.
- Collateral cleavage activity of Cas13a presents potential advantages with reduced genetic risks.
- Cas13a has shown success in viral diagnosis and elimination, but tumor therapy data is limited.
Conclusions:
- CRISPR-Cas13a is a promising tool for gene therapy due to its specificity and RNA-targeting ability.
- Further research is needed to determine the efficacy of Cas13a-based therapies in cancer treatment.
- Cas13a holds potential as a novel therapeutic strategy for oncological applications.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...